Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 89 entries
View as:

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05650203 Org: User:
Start: 03/31/23 End: 12/31/26 Due: 12/31/27

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

Phase: N/A Priority: Normal
NCT ID: NCT03301688 Org: User:
Start: 09/18/17 End: 12/15/19 Due: 12/15/20

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Phase: N/A Priority: Normal
NCT ID: NCT03924050 Org: User:
Start: 05/06/19 End: 08/08/24 Due: 08/08/25

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT06839105 Org: User:
Start: 02/21/25 End: 04/30/28 Due: 04/30/29

A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03430297 Org: User:
Start: 02/02/18 End: 11/27/23 Due: 11/27/24

Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04441918 Org: User:
Start: 06/05/20 End: 12/11/20 Due: 12/11/21

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03829969 Org: User:
Start: 01/31/19 End: 09/30/23 Due: 09/30/24

JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC）

Phase: N/A Priority: Normal
NCT ID: NCT06505837 Org: User:
Start: 07/11/24 End: 12/30/26 Due: 12/30/27

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03867370 Org: User:
Start: 04/26/19 End: 08/08/23 Due: 08/08/24

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04220073 Org: User:
Start: 01/05/20 End: 01/17/21 Due: 01/17/22

A Phase I Study Of JS015 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05770310 Org: User:
Start: 02/01/23 End: 07/01/25 Due: 07/01/26

The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor

Phase: N/A Priority: Normal
NCT ID: NCT06022250 Org: User:
Start: 09/26/23 End: 06/30/26 Due: 06/30/27

JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects

Phase: N/A Priority: Normal
NCT ID: NCT04780321 Org: User:
Start: 10/30/20 End: 08/31/21 Due: 08/31/22

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05253105 Org: User:
Start: 03/15/22 End: 01/31/27 Due: 01/31/28

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06571422 Org: User:
Start: 10/23/24 End: 04/30/27 Due: 04/30/28

Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04012606 Org: User:
Start: 07/23/19 End: 04/20/23 Due: 04/20/24

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Phase: N/A Priority: Normal
NCT ID: NCT05325203 Org: User:
Start: 12/31/21 End: 06/29/23 Due: 06/29/24

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06139211 Org: User:
Start: 01/03/24 End: 01/28/26 Due: 01/28/27

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02836834 Org: User:
Start: 08/31/16 End: 12/31/20 Due: 12/31/21

JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06969027 Org: User:
Start: 05/12/25 End: 12/31/27 Due: 12/31/28

A Phase I Study of JS108 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04601285 Org: User:
Start: 10/28/20 End: 06/14/23 Due: 06/14/24

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05180734 Org: User:
Start: 02/10/22 End: 07/31/28 Due: 07/31/29

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Phase: N/A Priority: Normal
NCT ID: NCT04515927 Org: User:
Start: 08/17/20 End: 07/29/22 Due: 07/29/23

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02836795 Org: User:
Start: 04/30/16 End: 12/17/18 Due: 12/17/19

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

Phase: N/A Priority: Normal
NCT ID: NCT05344248 Org: User:
Start: 01/20/21 End: 11/01/22 Due: 11/01/23